HIGHLIGHTS
- who: Ujunwa Cynthia Okoye-Okafor et al. from the approved by the Albert Einstein College of Medicine`s Institutional Review Board (#2016-6770)Healthy control BM and CB specimens were purchased from Lonza and the New York Blood Bank, respectively. MDS/AML patient samples were longitudinally collected before and after AZA treatment using a protocol approved by an ethics committee at Helsinki University Hospital (303/13/03/01/2011) and were processed at Institute for Molecular Medicine Finland (FIMM have published the Article: Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine, in the Journal: (JOURNAL . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.